Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

With studies showing potential for SGLT2 inhibitors in heart failure ... to consider its product’s role for heart failure patients who do not have diabetes. Heart failure is estimated to ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce the risk of heart failure," the authors noted in JAMA Internal Medicine.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

The FDA has approved the SGLT1 and SGLT2 inhibitor Inpefa as a once-daily oral therapy that can be used across a broad range of patients with or at risk of heart failure, including those with ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated ... and cardiovascular death. Heart failure (HF)-related outcomes comprised HF hospitalization, worsening HF symptoms, and HF-related ...

“These findings reinforce the use of dapagliflozin 10 mg, or other SGLT2 inhibitors, when the therapeutic goal is to reduce the risk of heart failure,” write HoJin ... which observational studies do ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

For example, someone with a new diagnosis of heart failure may start on a low dose of ARNI and beta-blocker, and within a few days or weeks, add a mineralocorticoid antagonist and SGLT2 inhibitor ...